Theratechnologies to Present Preliminary Safety and : vimars

Preliminary signs of antitumor activity noted in 36% of patients, with two partial responses (PR) and seven patients with prolonged stable disease (SD)...

Related Keywords

Chicago , Illinois , United States , Texas , Montreal , Quebec , Canada , American , Philippe Dubuc , Christian Marsolais , Julie Schneiderman , American Society Of Clinical Oncology , Theratechnologies Inc , University Of Texas Md Anderson Cancer Center , Communications Corporate Affairs , Department Of Investigational Cancer Therapeutics , Drug Administration , American Society , Clinical Oncology , Senior Vice President , Chief Medical Officer , Funda Meric Bernstam , Investigational Cancer Therapeutics , Saturday June , Developmental Therapeutics , Targeted Agents , Tumor Biology , Sudocetaxel Zendusortide , Fast Track , Forward Looking Statements , Looking Statements , Annual Information Form , Vice President , Chief Financial , Toronto Stock Exchange Th , Theratechnologies , Disco , Ncology , Dancer , Dc , Ortilin , H1902 ,